Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Pemetrexed Disodium
Synonyms
Therapy Description

Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Pemetrexed Disodium Alimta LY231514|Ciambra|pemetrexed Chemotherapy - Antimetabolite 14 Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03137771 Phase II Docetaxel Pemetrexed Disodium Gemcitabine Erlotinib Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Active, not recruiting USA | CAN 2
NCT02654587 Phase III OSE 2101 Pemetrexed Disodium Docetaxel Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) Terminated USA | ITA | GBR | FRA | ESP | DEU 4
NCT06096844 Phase III Nab-paclitaxel Pembrolizumab Carboplatin Pemetrexed Disodium Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial Recruiting USA 0
NCT04364048 Phase II Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT01107626 Phase III Pemetrexed Disodium Bevacizumab Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed USA 0
NCT03456076 Phase III Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS 19
NCT01928160 Phase II Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Withdrawn 0
NCT04380636 Phase III Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 19
NCT01828112 Phase III Docetaxel Pemetrexed Disodium Ceritinib LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 11
NCT02322281 Phase III Pemetrexed Disodium Gemcitabine Paclitaxel Docetaxel Rociletinib TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 2
NCT05973773 Phase III Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Zipalertinib Carboplatin + Pemetrexed Disodium + Zipalertinib Pemetrexed Disodium Cisplatin + Pemetrexed Disodium + Zipalertinib A Study of Zipalertinib and Chemotherapy Compared With Chemotherapy Alone in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion. (REZILIENT3) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 7
NCT03057106 Phase II Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Active, not recruiting CAN | AUS 0
NCT05583188 FDA approved Cisplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Carboplatin Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Cisplatin Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Pemetrexed Disodium Vinorelbine Gemcitabine Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Neoadjuvant Aliya PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC (VIGOR) Active, not recruiting USA 0
NCT01708993 Phase II Docetaxel Pemetrexed Disodium Pelareorep + Pemetrexed Disodium Docetaxel + Pelareorep Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Completed CAN 0
NCT01664754 Phase I Pemetrexed Disodium Carboplatin Exemestane Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer Completed USA 0
NCT03631199 Phase III Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 31
NCT00950365 Phase II Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT01553942 Phase II Afatinib Cisplatin Pemetrexed Disodium Afatinib With CT and RT for EGFR-Mutant NSCLC Unknown status USA 0
NCT01336842 Phase I Cisplatin Panobinostat Pemetrexed Disodium Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Completed USA 0
NCT01700400 Phase I Carboplatin Everolimus Bevacizumab Pemetrexed Disodium Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer Completed USA 0
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 22
NCT02387216 Phase II Seribantumab Pemetrexed Disodium Docetaxel A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC Terminated USA | FRA | ESP | DEU | CAN 1
NCT02079636 Phase I LY3023414 Abemaciclib Gemcitabine Pemetrexed Disodium Ramucirumab A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Completed USA | ESP 0
NCT02419495 Phase I Cyclophosphamide Pemetrexed Disodium Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin Selinexor in Combination With Standard Chemotherapy Active, not recruiting USA 0
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed 0
NCT01344824 Phase II Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers Completed USA 0
NCT04929041 Phase II Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Recruiting USA 0
NCT03083808 Phase II Gemcitabine + Pembrolizumab Docetaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Phase II Trial of Continuation Therapy in Advanced NSCLC Completed USA 0
NCT03257267 Phase III Irinotecan Gemcitabine Vinorelbine Pemetrexed Disodium Cemiplimab Topotecan Study of REGN2810 in Adults With Cervical Cancer Completed USA | ITA | GBR | ESP | CAN | BEL | AUS 7
NCT04943627 Phase III Topotecan Balstilimab Gemcitabine Irinotecan Pemetrexed Disodium Vinorelbine Balstilimab in Patients With Recurrent Cervical Cancer. Withdrawn USA 1
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Withdrawn 0
NCT02117024 Phase II Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Terminated USA 0
NCT02576574 Phase III Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin Avelumab in First-line NSCLC (JAVELIN Lung 100) Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 31
NCT04697628 Phase III Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Completed USA | CAN 0
NCT01646125 Phase II Docetaxel Luminespib Pemetrexed Disodium An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Terminated USA | NLD | ITA | GBR | FRA | ESP 6
NCT04547504 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE) Recruiting FRA 0
NCT02409342 Phase III Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Completed USA | ITA | GBR | FRA | ESP | DEU 13
NCT02264990 Phase III Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers Completed USA | NZL | NLD | GBR | ESP | DEU | CAN | AUS 12
NCT03737994 Phase II Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02134912 Phase II Crizotinib + Pemetrexed Disodium Pemetrexed Disodium S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Terminated USA 0
NCT06074588 Phase III Docetaxel SKB264 Pemetrexed Disodium MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Recruiting USA | CAN | AUS 6
NCT02574078 Phase Ib/II Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) Completed USA 0
NCT04205812 Phase III Retifanlimab Pemetrexed Disodium Carboplatin + Nab-paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Nab-paclitaxel + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Retifanlimab Carboplatin + Paclitaxel Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304) Active, not recruiting USA 16
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel Danvatirsen + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Active, not recruiting USA | ESP | BEL | AUT 5
NCT05184712 Phase III Carboplatin + Pemetrexed Disodium Ivonescimab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Ivonescimab + Pemetrexed Disodium Phase 3 Clinical Study of AK112 for NSCLC Patients Recruiting USA | ITA | FRA | ESP | CAN 1
NCT05635708 Phase II Nab-paclitaxel Cisplatin BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Recruiting USA | ITA | ESP | CAN | AUS 9
NCT03322566 Phase II Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) Completed USA | ITA | GBR | ESP | CAN | AUS 8


Additional content available in CKB BOOST